Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830797) titled 'Absorbable Hemostatic Fluid Gelatin Trial' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
Primary Sponsor: Medprin Regenerative Medical Technologies Co., Ltd.
Condition:
Surgical Bleeding
Intervention:
Device: Absorbable Hemostatic Fluid Gelatin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 8, 2026
Target Sample Size: 324
To know more, visit https://clinicaltrials.gov/study/NCT07830797
Published by HT Digital Content Services with pe...